Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes - Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011862

Enrollment

Registered

2013-10-02

Start date

2013-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Vildagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes inadequately controlled with sitaguliptin HbA1c(NGSP) of >= 7.0% 2)Patients with type 2 diabetes treated by diet and exercise therapy 3)Given informed consent

Exclusion criteria

Exclusion criteria: 1)Under insulin treatment (diabetic ketoacidosis , diabetic coma , type 1 diabetes , etc) 2)Has allergy to vildagliptin 3)Severe liver dammge 4)After severe infection,operation or injury 5)Patient who was considered to be appropriate to this study by attending physician

Design outcomes

Primary

Measure	Time frame
Surrogate marker(inflammation and oxidative stress) Continuous Glucose Monitoring	—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Naka Kinen Clinic Clinical Laboratory

k-ofuchi@kensei-kai.com029-353-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026